





Enson, Inc.

The **Enson Bioactive Surface™ (EBS)** is a proprietary surface treatment inspired by the body's natural non-thrombogenic and anti-inflammatory glycocalyx that lines the vasculature's interface. **EBS** effectively mitigates thrombogenic complications and prevents activation of foreign body response cascades including the adsorption of proteins, adherence and activation of platelets, monocytes, polymorphonuclear leukocytes and lymphocytes. **EBS** provides a superior and fully biocompatible interface for foreign materials that come into contact with the blood.


EBS can prevent clinical thrombogenic and inflammatory complications




NO thrombus formation on **EBS** treated stent



Thrombus formation on control stent




NO cell adhesion on **EBS** treated surface



Significant cell adhesion on control surface

The **EBS** modification process is cost-effective and customizable to a wide range of materials and particular medical device configurations. **EBS** maintains its bioactivity after double ethylene oxide sterilization cycles and two years of shelf-life.



The heparin bioactivity of **EBS** can be customized to specific biocompatibility needs of medical devices

EBS advantages include:

- Non-thrombogenic, anti-inflammatory, inhibits protein adsorption, prevents white cell activation
- Improvement in the efficiency of heparin attachment by functionalizing the surface using plasma enhanced chemical vapor surface activation.
- Stabilization of the heparin attachment to the activated surface by the use of covalent bonds that prevent heparin from leaching out of the surface.
- Optimization of overall biofunctionality of the attached heparin by suspending the heparin above the activated surface using a charge balance and collapse-resistant technologies.

